Company Description
Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific.
It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats.
In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs.
It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.
It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.
Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 10, 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 534 |
| CEO | Dr. Michael Egholm Ph.D. |
Contact Details
Address: 2 Tower Place, Suite 2000 South San Francisco, California 94080 United States | |
| Phone | (650) 266-6000 |
| Website | fluidigm.com |
Stock Details
| Ticker Symbol | LAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001162194 |
| CUSIP Number | 34385P108 |
| ISIN Number | US34385P1084 |
| Employer ID | 77-0513190 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Egholm Ph.D. | President, Chief Executive Officer and Director |
| Hanjoon Kim | Chief Operating Officer |
| Jeffrey G. Black | Chief Financial Officer |
| Dr. Shane Bowen Ph.D. | Chief Technology Officer |
| Adam Taich | Chief Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 8-K | Current Report |
| Jun 27, 2024 | EFFECT | Notice of Effectiveness |
| Jun 24, 2024 | 144 | Filing |
| Jun 24, 2024 | 144 | Filing |
| Jun 24, 2024 | 144 | Filing |
| Jun 20, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jun 3, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 3, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 3, 2024 | 8-K | Current Report |
| May 29, 2024 | SD | Form - SD |